Skip to main content
. 2023 Nov 16;14:1223746. doi: 10.3389/fphar.2023.1223746

FIGURE 2.

FIGURE 2

LSEQ scores of dexmedetomidine (DEX) and placebo groups. The LSEQ scores for “getting to sleep” (GTS) and “quality of sleep” (QOS) were significantly increased in the DEX group compared to baseline, while the scores consistently remained lower than baseline in the placebo group. In terms of “awakening from sleep” (AFS) and “behavior following wakefulness” (BFW), the placebo group scores were lower than those of the DEX group. The subjective improvements in sleep quality resulting from DEX treatment were reflected in easier sleep onset and better overall sleep quality.